Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REVLIMID vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality,Mantle cell lymphoma,Follicular lymphoma (in combination with rituximab)
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Lenalidomide is primarily metabolized via hydrolysis, with minor involvement of CYP1A2 and CYP3A4. The major route of elimination is renal excretion of unchanged drug; approximately 67% of the dose is excreted unchanged in urine.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Approximately 30% bound to plasma proteins, primarily albumin.
30-35% bound to albumin.
Volume of distribution (Vd) is approximately 0.6-1.0 L/kg, indicating distribution into total body water and some tissue binding.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Absolute oral bioavailability is approximately 33% (range 20-50%) due to first-pass metabolism. Food does not significantly alter bioavailability.
Oral: 70-85% with high variability; intrathecal: 100%.
For Cr Cl ≥60 m L/min: start at 10 mg daily; Cr Cl 30-60 m L/min: start at 5 mg daily; Cr Cl <30 m L/min: 5 mg every other day; for dialysis patients: 5 mg three times weekly after dialysis.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
No specific Child-Pugh based dose adjustments provided in labeling; use caution and monitor for toxicity in hepatic impairment.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Safety and efficacy not established; not recommended for pediatric use outside clinical trials.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
No specific dose adjustment based solely on age; monitor renal function and adjust per renal guidelines as elderly often have decreased Cr Cl.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Revlimid (lenalidomide) can cause fetal harm. Women of childbearing potential must use effective contraception and undergo pregnancy testing prior to and during therapy. There is an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. The drug is contraindicated in pregnant women.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Hematologic toxicity: Neutropenia and thrombocytopenia are common, requiring dose adjustments.,Thromboembolism: Increased risk of DVT, PE, and stroke; consider prophylactic anticoagulation or antiplatelet therapy.,Second primary malignancies: Risk of development of other cancers (e.g., AML, MDS) in patients receiving lenalidomide.,Hepatotoxicity: Elevations of liver enzymes have been reported.,Allergic reactions: Including angioedema and Stevens-Johnson syndrome.,Renal impairment: Requires dose adjustment; monitor renal function.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Pregnancy (due to teratogenicity),Women of childbearing potential not using effective contraception,Hypersensitivity to lenalidomide or any component of the formulation
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Avoid grapefruit and grapefruit juice; they may increase lenalidomide exposure. No other significant food interactions are known.
No specific food interactions. Avoid alcohol due to additive CNS depression.
REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth defects including limb reduction, cardiac anomalies, and neural tube defects. Risk is highest during the first trimester but extends throughout gestation.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
It is unknown if lenalidomide is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated. M/P ratio is not available.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
There are no dose adjustments for pregnancy because the drug is contraindicated; it must be discontinued immediately if pregnancy occurs. No pharmacokinetic studies in pregnancy are available.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Monitor for thromboembolic events; use with aspirin or anticoagulant prophylaxis. Perform pregnancy tests weekly during first month, then monthly in women of childbearing potential. Dose reduce for Cr Cl <60 m L/min. Avoid in severe hepatic impairment (Child-Pugh C).
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Do not share this medication with others; it can cause severe birth defects.,Use two forms of contraception or abstain from sex during treatment and for 4 weeks after stopping.,Report any new shortness of breath, chest pain, or leg swelling immediately.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not donate blood during treatment and for 4 weeks after stopping.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REVLIMID vs BACLOFEN, answered by our medical review team.
REVLIMID is a Immunomodulatory Agent that works by Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REVLIMID and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REVLIMID is: 5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REVLIMID and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REVLIMID is classified as Category C. REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.